Cargando…

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients

Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic profiling for the prognosis and predicting benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiaofu, Dent, Susan, Paquet, Lise, Zhang, Tinghua, Tesolin, Daniel, Graham, Nadine, Aseyev, Olexiy, Song, Xinni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985759/
https://www.ncbi.nlm.nih.gov/pubmed/33557029
http://dx.doi.org/10.3390/curroncol28010077
_version_ 1783668316061040640
author Zhu, Xiaofu
Dent, Susan
Paquet, Lise
Zhang, Tinghua
Tesolin, Daniel
Graham, Nadine
Aseyev, Olexiy
Song, Xinni
author_facet Zhu, Xiaofu
Dent, Susan
Paquet, Lise
Zhang, Tinghua
Tesolin, Daniel
Graham, Nadine
Aseyev, Olexiy
Song, Xinni
author_sort Zhu, Xiaofu
collection PubMed
description Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic profiling for the prognosis and predicting benefit of chemotherapy, we surveyed medical oncologists in Canada to assess their usage and perception of the ODX assay. Methods: A 34-item survey was distributed to Canadian medical oncologists via the Canadian Association of Medical Oncologists. Data was collected on physician demographics, ODX usage patterns, and physicians’ perception of the impact clinical and pathologic characteristics make on ODX utilization. Results: Response rate was 20.6% with 47 responses received from 228 survey sent. Forty-five responses were eligible for analysis. Sixty-two percent (28/45) of respondents treated predominantly breast cancer, and 60% (27/45) have been in practice for at least 10 years. The most cited reason for using ODX was to avoid giving patients unnecessary chemotherapy (64%; 29/45). Sixty-seven percent (30/45) deferred making treatment decisions until ODX testing was completed. Factors most strongly impacting ODX utilization included: patient request, medical comorbidities and tumor grade. In clinical scenarios, ODX was more frequently selected for patients aged 40–65 (vs. <40 or >65), grade 2 tumors (vs. grade 1 or 3), and Ki-67 index of 10–20% (vs. <10% or >20%). Conclusions: This survey demonstrated that Canadian medical oncologists are preferentially using ODX to avoid giving patients unnecessary chemotherapy. The utilization of ODX is mainly in patients with intermediate clinical and pathologic features.
format Online
Article
Text
id pubmed-7985759
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79857592021-03-24 How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients Zhu, Xiaofu Dent, Susan Paquet, Lise Zhang, Tinghua Tesolin, Daniel Graham, Nadine Aseyev, Olexiy Song, Xinni Curr Oncol Article Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic profiling for the prognosis and predicting benefit of chemotherapy, we surveyed medical oncologists in Canada to assess their usage and perception of the ODX assay. Methods: A 34-item survey was distributed to Canadian medical oncologists via the Canadian Association of Medical Oncologists. Data was collected on physician demographics, ODX usage patterns, and physicians’ perception of the impact clinical and pathologic characteristics make on ODX utilization. Results: Response rate was 20.6% with 47 responses received from 228 survey sent. Forty-five responses were eligible for analysis. Sixty-two percent (28/45) of respondents treated predominantly breast cancer, and 60% (27/45) have been in practice for at least 10 years. The most cited reason for using ODX was to avoid giving patients unnecessary chemotherapy (64%; 29/45). Sixty-seven percent (30/45) deferred making treatment decisions until ODX testing was completed. Factors most strongly impacting ODX utilization included: patient request, medical comorbidities and tumor grade. In clinical scenarios, ODX was more frequently selected for patients aged 40–65 (vs. <40 or >65), grade 2 tumors (vs. grade 1 or 3), and Ki-67 index of 10–20% (vs. <10% or >20%). Conclusions: This survey demonstrated that Canadian medical oncologists are preferentially using ODX to avoid giving patients unnecessary chemotherapy. The utilization of ODX is mainly in patients with intermediate clinical and pathologic features. MDPI 2021-02-04 /pmc/articles/PMC7985759/ /pubmed/33557029 http://dx.doi.org/10.3390/curroncol28010077 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhu, Xiaofu
Dent, Susan
Paquet, Lise
Zhang, Tinghua
Tesolin, Daniel
Graham, Nadine
Aseyev, Olexiy
Song, Xinni
How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
title How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
title_full How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
title_fullStr How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
title_full_unstemmed How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
title_short How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
title_sort how canadian oncologists use oncotype dx for treatment of breast cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985759/
https://www.ncbi.nlm.nih.gov/pubmed/33557029
http://dx.doi.org/10.3390/curroncol28010077
work_keys_str_mv AT zhuxiaofu howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients
AT dentsusan howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients
AT paquetlise howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients
AT zhangtinghua howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients
AT tesolindaniel howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients
AT grahamnadine howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients
AT aseyevolexiy howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients
AT songxinni howcanadianoncologistsuseoncotypedxfortreatmentofbreastcancerpatients